Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19.

ABSTRACT:

Background and aim

Cytokine release syndrome is a dangerous complication of the coronavirus disease 2019 (COVID-19). This study aimed to evaluate the efficacy and safety of tofacitinib in the management of this complication.

Methods

The retrospective study included COVID-19 patients with C-reactive protein (CRP) levels of 60-150 mg/L.

Results

Thirty-two patients who received tofacitinib (TOF group) and 30 patients who did not receive any anti-cytokine drugs (control [CON] group) were enrolled. Mortality and the incidence of admission to the intensive care unit were lower in the TOF group than in the CON group (16.6% vs. 40.0%, p = 0.009; and 15.6% vs. 50.0%, p = 0.004). There was a significant decrease in the volume of the affected part of the lungs (p = 0.022) and a

SUBMITTER: Maslennikov R 

PROVIDER: S-EPMC8137353 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature